Paradromics stock
Private-market facts for current and former Paradromics employees researching their stock.
Overview
Paradromics develops high-bandwidth brain-computer interfaces with thousands of electrodes for restoring speech and motor function to people with paralysis.
Paradromics outlook
For employees evaluating Paradromics equity, a 2x base multiple suggests limited near-term upside at current levels. The upside scenario at 4x is relatively close to the base case, suggesting more predictable but narrower range of outcomes.
These estimates reflect modeled return scenarios, not guaranteed outcomes. Actual results depend on company performance, market conditions, share class, and timing.
Selling Paradromics shares
Why shareholders consider selling
Shareholders in Paradromics may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Paradromics does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Paradromics stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Paradromics shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Paradromics shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series B round can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Paradromics shareholders
Exploring equity in Paradromics often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Paradromics most recently raised a Series B round . Total funding raised to date is approximately $85M.
Founders & company background
Paradromics was founded in 2015 by Matt Angle and is headquartered in Austin, TX.
Industry
Similar private companies
Latest Paradromics news
Frequently asked questions
- Is Paradromics still a private company?
- Yes, Paradromics is currently a private company.
- What is Paradromics's latest funding round?
- Paradromics's most recent known round is Series B.
- What is Paradromics's valuation?
- Paradromics's valuation has not been publicly disclosed.
- Who are the investors in Paradromics?
- Investor information is not currently available.
- Can I sell my Paradromics stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Paradromics stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Paradromics data compiled from funding disclosures, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.